--- title: "Addex Therapeutics (ADXN) news: offering and Nasdaq notice" url: "https://aibio.space/companies/addex-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADXN offering and Nasdaq notice news: Addex amends H.C. Wainwright ATM deal for up to $3,300,000 of ADSs. Addex Therapeutics Ltd (SIX: ADXN), Switzerland." --- ADXN Addex Therapeutics Ltd SIX · Switzerland # Addex Therapeutics (ADXN) news ADXN offering and Nasdaq notice news Distress · 2026-04-30 ## [Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F](https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/) Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business. ## Latest Addex Therapeutics news 1. 2025-12-10 Financings [Addex amends H.C. Wainwright ATM deal for up to $3,300,000 of ADSs](https://aibio.space/news/addex-amends-h-c-wainwright-atm-deal-up-3-300-000-adss/) Addex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026. ## Addex Therapeutics at a glance - **Ticker**: ADXN - **Listing**: SIX - **Country**: Switzerland - **Cash, Jun 30, 2025**: CHF 2.3 million ### Related companies - [Galderma Group](https://aibio.space/companies/galderma/) SIX: GALD - [Novartis](https://aibio.space/companies/novartis/) SIX: NOVN - [Bachem Holding](https://aibio.space/companies/bachem/) SIX: BANB - [ADC Therapeutics SA](https://aibio.space/companies/adc-therapeutics/) NYSE: ADCT - [Basilea Pharmaceutica](https://aibio.space/companies/basilea-pharmaceutica/) SIX: BSLN - [MoonLake Immunotherapeutics](https://aibio.space/companies/moonlake-immunotherapeutics/) NASDAQ: MLTX - [BeOne Medicines](https://aibio.space/companies/beone-medicines/) SSE: 688235 - [Sandoz Group](https://aibio.space/companies/sandoz/) SIX: SDZ ### Also on SIX - [Bachem Holding](https://aibio.space/companies/bachem/) BANB - [Santhera Pharmaceuticals Holding](https://aibio.space/companies/santhera-pharmaceuticals/) SANN - [Siegfried Holding](https://aibio.space/companies/siegfried/) SFZN - [MindMaze Therapeutics Holding SA](https://aibio.space/companies/mindmaze-therapeutics/) MMTX - [Sandoz Group](https://aibio.space/companies/sandoz/) SDZ - [Molecular Partners](https://aibio.space/companies/molecular-partners/) MOLN ## What Addex Therapeutics does Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company, founded in 2002 and registered in Geneva, Switzerland, focused on the development of orally available small molecule drug candidates. Its pipeline consists of proprietary clinical and preclinical candidates that the company or its partners are developing for diseases where no approved therapies exist or improved therapies are needed, including post-stroke sensorimotor recovery, traumatic brain injury (TBI) recovery, substance use disorders and chronic cough. Its lead development compound is dipraglurant, an mGlu5 negative allosteric modulator under evaluation for future development in post-stroke and TBI recovery. On April 30, 2025, the company entered into an option and collaboration agreement with Sinntaxis AB for an exclusive license covering mGlu5 inhibitors for brain injury recovery. Partner Indivior has licensed worldwide rights to a GABAB positive allosteric modulator for substance use disorder and has completed IND enabling studies on its selected compound. Addex plans its own GABAB program for chronic cough. The company also holds a 20% equity interest in Neurosterix US Holdings LLC, a company developing preclinical candidates for schizophrenia and mood disorders. | Product or program | What it is | Stage | |---|---|---| | Dipraglurant | mGlu5 negative allosteric modulator for post-stroke and TBI recovery | under evaluation for future development | | ADX71149 | mGlu2 positive allosteric modulator returned by partner Janssen | under evaluation | | GABAB PAM for substance use disorder | Licensed to partner Indivior, which holds worldwide rights | IND enabling studies completed by partner | | GABAB PAM for chronic cough | Company-selected compound with preclinical anti-tussive activity | planned IND enabling studies | Summarised from the company's [20-F filed May 15, 2026](https://www.sec.gov/Archives/edgar/data/1574232/000110465926062447/adxn-20251231x20f.htm). ## Addex Therapeutics annual financials | Line | FY2024 | FY2023 | |---|---|---| | Revenue | [CHF 404,102](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | [CHF 1.6 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | | Research and development | [CHF 854,305](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | [CHF 1.2 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | | Net income (loss) | [CHF 7.1 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | [-CHF 10.6 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | | Cash from operations | [-CHF 5.4 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | [-CHF 8.0 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | | Cash and equivalents | [CHF 3.3 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925094663/) | [CHF 3.9 million](https://www.sec.gov/Archives/edgar/data/1574232/000110465925094663/) | | Short-term investments | [CHF 6,496](https://www.sec.gov/Archives/edgar/data/1574232/000110465925094663/) | [CHF 848](https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/) | Latest balance sheet, Jun 30, 2025 (6-K): cash and equivalents CHF 2.3 million, plus short-term investments of CHF 6,994, CHF 2.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Addex Therapeutics Has Addex Therapeutics raised money recently? Our latest story on this, dated Dec 10, 2025: "Addex amends H.C. Wainwright ATM deal for up to $3,300,000 of ADSs". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/addex-amends-h-c-wainwright-atm-deal-up-3-300-000-adss/). Has Addex Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Apr 30, 2026: "Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/). What is the ticker symbol of Addex Therapeutics? Addex Therapeutics Ltd trades under the ticker ADXN on SIX. Where is Addex Therapeutics listed? Addex Therapeutics Ltd is listed on SIX. Our directory also records these other listings: GETTEX:APE; LSE:0QNV; NASDAQ:ADXN. What is the SEC CIK of Addex Therapeutics? The SEC Central Index Key (CIK) for Addex Therapeutics Ltd is 1574232. Its filings are on SEC EDGAR. How many shares does Addex Therapeutics have outstanding? 147,831,814 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15. Which country or territory is Addex Therapeutics listed under? Our directory records Addex Therapeutics Ltd under Switzerland. What does Addex Therapeutics do? Our directory classifies Addex Therapeutics Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Addex Therapeutics? The ISIN recorded for Addex Therapeutics Ltd is CH0029850754. Does aibio.space cover Addex Therapeutics? aibio.space lists Addex Therapeutics Ltd among 2,820 public biotech companies and publishes its news here as stories appear. Where is Addex Therapeutics incorporated? SEC records list its state or country of incorporation as V8. What does Addex Therapeutics develop? Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company, founded in 2002 and registered in Geneva, Switzerland, focused on the development of orally available small molecule drug candidates. Its pipeline consists of proprietary clinical and preclinical candidates that the company or its partners are developing for diseases where no approved therapies exist or improved therapies are needed, including post-stroke sensorimotor recovery, traumatic brain injury (TBI) recovery, substance use disorders and chronic cough. What is Dipraglurant from Addex Therapeutics? Dipraglurant: mGlu5 negative allosteric modulator for post-stroke and TBI recovery Stage: under evaluation for future development. What is ADX71149 from Addex Therapeutics? ADX71149: mGlu2 positive allosteric modulator returned by partner Janssen Stage: under evaluation. What is the latest Addex Therapeutics (ADXN) stock news? Our latest story on Addex Therapeutics, dated Apr 30, 2026: "Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F". Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business. [Source](https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/). ## Investor discussion: Addex Therapeutics Members talk about Addex Therapeutics (ADXN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Addex Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-04-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1574232/000110465926052854/tm261156d2_nt20f.htm) 2. 2025-12-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1574232/000110465925119967/tm2531595-4_424b5.htm) 3. 2025-04-30 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1574232/000110465925042472/tm251277d2_nt20f.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open SIX:ADXN on TradingView](https://www.tradingview.com/symbols/SIX-ADXN/). ## SEC filings and registration - **SEC name**: Addex Therapeutics Ltd. - **CIK**: 1574232 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ADXN (Nasdaq) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: CHEMIN DES MINES 9, GENEVA, Switzerland, CH-1202 - **Phone**: 01141228841555 - **Shares outstanding**: 147,831,814 as of 2025-12-31 (20-F filed 2026-05-15) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326006524/f6k_100826.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326006345/f6k_100226.htm) filed 2026-10-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000110465926111142/adxn-20260630x6k.htm) filed 2026-09-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326006225/f6k_092526.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326005744/f6k_082626.htm) filed 2026-08-26 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326004524/f6k_070826.htm) filed 2026-07-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000117184326004375/f6k_063026.htm) filed 2026-06-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1574232/000110465926077470/tm2618934d1_6k.htm) filed 2026-06-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001574232), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Addex Therapeutics Ltd is a public biotech or pharmaceutical company listed on SIX under the ticker ADXN, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Addex Therapeutics Ltd - **Ticker**: ADXN - **Listing**: SIX - **Country or territory**: Switzerland - **Business scope**: Pharmaceuticals: Major - **ISIN**: CH0029850754 - **Other listed symbols**: GETTEX:APE; LSE:0QNV; NASDAQ:ADXN - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/SIX-ADXN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/addex-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Addex Therapeutics (ADXN) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/addex-therapeutics/